Asset profile
RBD7022
RNA / oligonucleotide
Evidence outlook · lead readout
NCT05912296 · Hyperlipemia
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05912296: The study randomly assigned participants to RBD7022 or a matching placebo with the participant kept unaware of assignment, but it was a small, single-masked Phase 1 safety study, and no results are posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.